

Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation for Refractory Systemic Sclerosis and Cancer Patients Undergoing Radiotherapy

S. Tong¹, Z. Liu¹, Q. Wen², X. Zhang², C. Zheng^{1*}

¹Department of Hematology, Rheumatology and Immunology, Pu'er People's Hospital, Pu'er, China

²Hematology Center, Second Affiliated Hospital of Army Medical University, Chongqing, China

ABSTRACT

► Original article

*Corresponding author:

Chaoen Zheng, M.D.,

E-mail: onrx855@163.com

Received: June 2025

Final revised: July 2025

Accepted: July 2025

Int. J. Radiat. Res., January 2026;
24(1): 173-178

DOI: 10.61186/ijrr.24.1.26

Keywords: Systemic Sclerosis, Neoplasms, Radiotherapy, Hematopoietic Stem Cell Transplantation, Autologous, CD34 Antigen.

Background: To evaluate the clinical effectiveness of autologous peripheral blood hematopoietic stem cell transplantation (Auto-HSCT) as a therapeutic approach for patients with both refractory systemic sclerosis (SSc) and cancer undergoing radiotherapy. **Materials and Methods:** Eleven patients with refractory SSc and concurrent cancer received Auto-HSCT following peripheral blood stem cell mobilization. Standardized radiotherapy protocols were applied based on cancer type. Preconditioning regimens included combinations of cyclophosphamide, melphalan, rituximab, and bendamustine. Post-transplant assessments focused on hematopoietic recovery, SSc disease activity, and tumor response. **Results:** A mean of $3.87 \times 10^6/\text{kg}$ CD34+ cells were collected. All patients achieved hematopoietic reconstitution, with neutrophil and platelet recovery occurring in 9 ± 3 and 14 ± 7 days, respectively. At a median follow-up of 14.6 months, improvements in modified Rodnan skin scores (mRSS), digital ulcers, Raynaud's phenomenon, and pulmonary fibrosis were observed. Eight patients showed sustained improvement in SSc and cancer response. Three patients relapsed and required additional immunotherapy. **Conclusion:** Auto-HSCT appears to be a feasible and effective option for patients with both refractory SSc and cancer undergoing radiotherapy. It improved autoimmune disease control, enhanced hematopoietic recovery, and supported cancer treatment with manageable toxicity.

INTRODUCTION

Systemic sclerosis (SSc), a systemic autoimmune disease, is characterized by microvascular damage, immune dysregulation, and extensive fibrosis of the skin and internal organs, such as the lungs, heart, and kidneys (1,2). Patients with refractory SSc face a poor prognosis, with limited treatment options and a 5-year mortality rate exceeding 60% in high-risk cases with diffuse, rapidly progressive disease (3,4). Concurrently, cancer patients undergoing radiotherapy often experience significant hematologic toxicity, including bone marrow suppression, which compromises treatment tolerance and increases risks of infections and bleeding (5). Recent studies confirm the hematopoietic burden of radiation; over 50% of cervical cancer patients receiving chemoradiation develop grade ≥ 2 hematologic toxicity, linked to bone marrow exposure during radiotherapy (6). A 2024 Lancet review further emphasized the unmet need for marrow-sparing strategies during radiation therapy, especially in immune-compromised hosts (7). The coexistence of refractory SSc and cancer in patients undergoing radiotherapy presents a unique clinical challenge, as both conditions contribute to significant morbidity and require innovative therapeutic strategies to address autoimmune activity, tumor

progression, and radiotherapy-induced myelosuppression.

Autologous peripheral blood hematopoietic stem cell transplantation (Auto-HSCT) has emerged as a promising approach for managing refractory autoimmune diseases and supporting cancer patients undergoing intensive treatments (8). By collecting and reinfusing a patient's own CD34+ hematopoietic stem cells, Auto-HSCT facilitates hematopoietic reconstitution, mitigates radiotherapy-induced bone marrow suppression, and modulates immune responses in autoimmune conditions like SSc (9). Unlike allogeneic transplantation, Auto-HSCT offers a lower risk of complications, such as graft-versus-host disease, making it a safer option for complex cases. Its efficacy has been demonstrated in autoimmune diseases, including SSc, multiple sclerosis, and Crohn's disease, as well as in supporting hematologic recovery in oncology settings (10). A recent meta-analysis reported that Auto-HSCT significantly improved skin scores, pulmonary outcomes, and survival in patients with SSc, with a transplant-related mortality rate of approximately 6% (11). Moreover, advancements in transplant protocols—such as cardiac-safe regimens—have enhanced safety even in patients with SSc-related myocarditis (12).

To our knowledge, this is the first study to evaluate Auto-HSCT as a dual-purpose strategy in

patients with both refractory SSc and concurrent cancer undergoing radiotherapy, aiming to modulate autoimmunity and protect hematopoietic integrity in a single, integrated therapeutic approach.

To evaluate the safety and efficacy of Auto-HSCT in patients with both refractory SSc and cancer undergoing radiotherapy, this study retrospectively analyzed 11 patients treated at the Department of Hematology, Rheumatology, and Oncology of Pu'er People's Hospital from January 2019 to March 2023, assessing its impact on SSc disease activity, tumor response, hematopoietic recovery, and clinical outcomes.

MATERIALS AND METHODS

Clinical data

Eleven patients diagnosed with both refractory systemic sclerosis (SSc) and cancer, all undergoing radiotherapy, were enrolled at the Department of Hematology, Rheumatology, and Oncology of Pu'er People's Hospital from January 2019 to March 2023. All patients met the 2013 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) classification criteria for SSc⁽¹³⁾. The cohort included 8 females and 3 males, with a

mean age of 46.5 years (range: 32–61). Cancer types included breast cancer (4 patients), lung cancer (3), lymphoma (2), esophageal cancer (1), and pancreatic cancer (1). SSc-related complications included interstitial lung disease (7 patients), arthritis (6), digital ulcers (4), overlapping systemic lupus erythematosus with hemophagocytic syndrome (1), rheumatoid arthritis (1), and penile atrophy (1). Detailed baseline characteristics are summarized in table 1. The modified Rodnan skin score (14)(mRSS) before transplantation was >25 points, indicating severe skin involvement. All patients had received standardized immunosuppressive therapy (e.g., cyclophosphamide, azathioprine, or mycophenolate mofetil) for SSc and/or chemotherapy for cancer for over six months prior to enrollment, with poor response (persistent mRSS elevation, worsening skin fibrosis, esophageal involvement, Raynaud's phenomenon, non-healing fingertip ulcers, and/or progressive tumor activity). High-resolution computed tomography (HRCT) confirmed persistent pulmonary interstitial fibrosis in SSc cases. Exclusion criteria included active tuberculosis, acute or chronic hepatitis (A, B, or C), severe cardiac, pulmonary, or renal dysfunction, active bacterial or fungal infections, pregnancy, or lactation.

Table 1. Detailed characteristics of patients enrolled in the study.

Case	Age (years)	Sex	Cancer Type	SSc Subtype / Overlap	Baseline mRSS	Preconditioning Regimen	Follow-up (months)
1	45	F	Breast	dcSSc + PBC	32	RTX + Benda + CTX	28
2	48	F	Lymphoma	dcSSc + SLE + HLH	32	Mel + Benda	28
3	42	M	Lung	dcSSc	32	Mel	28
4	40	F	Breast	dcSSc	28	RTX + Benda + CTX	36
5	43	M	Lung	dcSSc	28	Mel + Benda	30
6	54	F	Esophageal	dcSSc	32	Mel + CTX	18
7	46	F	Lymphoma	dcSSc + RA	32	Mel + Benda	14
8	39	F	Breast	dcSSc	40	CTX	14
9	37	F	Breast	dcSSc	28	CTX	12
10	52	M	Lung	dcSSc	32	Mel	12
11	61	M	Pancreatic	dcSSc	32	CTX	6

Abbreviations: mRSS = modified Rodnan skin score; dcSSc = diffuse cutaneous systemic sclerosis; PBC = primary biliary cholangitis; SLE = systemic lupus erythematosus; HLH = hemophagocytic lymphohistiocytosis; RA = rheumatoid arthritis; RTX = rituximab; Benda = bendamustine; CTX = cyclophosphamide; Mel = melphalan.

Radiotherapy protocol

Radiotherapy was administered based on cancer type and stage, following standard oncology guidelines. Patients with breast cancer received external beam radiotherapy (EBRT) with a total dose of 50–60 Gy in 1.8–2.0 Gy fractions over 5–6 weeks. Lung cancer patients received stereotactic body radiotherapy (SBRT) for early-stage disease (50–60 Gy in 3–5 fractions) or conventional EBRT for advanced stages (60–66 Gy in 2.0 Gy fractions). Lymphoma patients underwent involved-site radiotherapy (ISRT), while patients with other solid tumors received EBRT tailored to tumor size and location.

All radiotherapy was performed using a Varian TrueBeam® linear accelerator (Varian Medical Systems, Palo Alto, USA). Treatment planning was conducted with the Eclipse™ Version 16.1 software

(Varian Medical Systems), incorporating CT-based 3D conformal or intensity-modulated radiotherapy (IMRT) protocols. Daily image-guided radiotherapy (IGRT) was employed to ensure precision.

Mobilization strategy

Peripheral blood stem cell mobilization was performed using cyclophosphamide (CTX) at 2.0 g/m² intravenously for 2 days, followed by recombinant human granulocyte colony-stimulating factor (G-CSF) at 10 µg/kg/day subcutaneously for 4 days when white blood cell counts began to recover post-nadir. Plerixafor (Mozobil) at 0.24 mg/kg was administered subcutaneously 11 hours before collection. Stem cell collection proceeded when white blood cell counts exceeded 5 × 10⁹/L and platelet counts exceeded 50 × 10⁹/L, targeting ≥2 × 10⁶/kg CD34+ cells and ≥5 × 10⁸/kg mononuclear cells (MNC). Collected cells were

cryopreserved in a -80°C freezer using a preservation solution.

All apheresis procedures were performed using the COBE Spectra system (Terumo BCT, USA), and cryopreservation used CryoMACS® freezing bags (Miltenyi Biotec, Germany). Cyclophosphamide, melphalan, and bendamustine were sourced from Baxter (USA); rituximab from Roche (Switzerland); plerixafor from Sanofi (France); and G-CSF from Kyowa Kirin (Japan).

Preconditioning regimens

Patients received one of the following preconditioning regimens: four patients received rituximab (375 mg/m² on day -8), bendamustine (90 mg/m² on days -7 to -6), and CTX (50 mg/kg on days -5 to -2); six patients received melphalan (Mel)-based regimens (three with Mel at 70 mg/m² on day -3 alone, two with Mel at 70 mg/m² on day -3 plus bendamustine at 90 mg/m² on days -5 to -4, and one with Mel at 70 mg/m² on day -3 plus CTX at 50 mg/kg on days -7 to -4); one patient received CTX alone (50 mg/kg on days -5 to -2).

Supportive Care and Complication Prevention

One week prior to entering the laminar flow ward, patients initiated oral levofloxacin and trimethoprim-sulfamethoxazole for gut decontamination, shaved body hair, and underwent a 1:2000 chlorhexidine bath. A peripherally inserted central catheter (PICC) was placed in the elbow vein before ward entry. Following high-dose CTX, mesna was administered to prevent hemorrhagic cystitis. Platelet transfusions were provided when counts fell below $20 \times 10^9/L$ or during active bleeding, and red blood cell transfusions were given when hemoglobin was <60 g/L. G-CSF (5 µg/kg) was administered 2 days post-Auto-HSCT to promote hematopoietic reconstitution. Broad-spectrum antibiotics were used for infections associated with granulocytopenia.

Post-transplant monitoring

Post-transplant assessments included hematopoietic reconstitution (time to neutrophil [ANC] $>0.5 \times 10^9/L$ and platelet [PLT] $>20 \times 10^9/L$), SSc disease activity (via mRSS), tumor response (per RECIST criteria for solid tumors or relevant hematologic response criteria), clinical symptoms (e.g., skin fibrosis, Raynaud's phenomenon, digital ulcers), and laboratory indicators (e.g., antinuclear antibody [ANA] titer, anti-SCL-70 antibody, and tumor markers). Evaluations were conducted at 3-, 4-, and 6-months post-transplantation, and then every 6 months as needed. The median follow-up duration was 14.6 months (range: 6–36 months).

Statistical analysis

Data were analyzed using SPSS 26.0 (IBM Corp., Armonk, NY, USA). Quantitative data were expressed

as mean $\pm$ standard deviation. Categorical data were reported as frequencies and percentages. Comparisons before and after transplantation were performed using paired t-tests or Wilcoxon signed-rank tests, depending on data distribution. Confidence intervals (95% CI) were calculated for key outcomes (e.g., mRSS, tumor response). A p-value < 0.05 was considered statistically significant.

Ethics

This study was approved by the Ethics Committee of Pu'er People's Hospital (Ethics Approval No.: SKJJ-2024-02) and conducted in accordance with the Declaration of Helsinki. The study was formally registered on March 12, 2024. All patients provided written informed consent prior to participation.

RESULTS

Mobilization and collection of peripheral blood stem cells

All patients successfully underwent stem cell mobilization and collection. G-CSF was initiated 6–10 days after CTX in all 11 patients. Collection was completed in one session for 3 patients, two sessions for 7 patients, and three sessions for 1 patient. The median mononuclear cell (MNC) yield was $5.91 \times 10^8/kg$ (range: $3.5\text{--}8.0 \times 10^8/kg$), and the median CD34+ cell count was $3.87 \times 10^6/kg$ (range: $1.5\text{--}5.4 \times 10^6/kg$).

Hematopoietic reconstitution

All patients achieved prompt hematopoietic recovery following Auto-HSCT. The median neutrophil recovery time (ANC $>0.5 \times 10^9/L$) was 9 ± 3 days, and the median platelet recovery time (PLT $>20 \times 10^9/L$) was 14 ± 7 days.

Radiotherapy outcomes

Radiotherapy resulted in favorable tumor responses in most patients. Among breast cancer cases (n=4), 3 achieved partial response (PR) and 1 had stable disease (SD). Among lung cancer patients (n=3), 2 achieved complete response (CR) with SBRT, and 1 had PR after EBRT. Both lymphoma patients achieved CR. Among other cancers, 1 (esophageal) had PR, and 1 (pancreatic) had SD. Figure 1 shows response distribution across tumor types.

Radiotherapy-related toxicities were manageable: grade 1–2 erythema (n=6), mild fatigue (n=8), and grade 1 mucositis (n=3). No grade 3–4 adverse events were reported.

Effectiveness on systemic sclerosis and clinical improvement

Post-transplant follow-up revealed significant improvement in SSc symptoms and biomarkers. At 3 and 6 months, mean mRSS decreased by 18 ± 5

points. Clinical symptoms such as skin thickening, Raynaud's, and digital ulcers improved in most patients. Table 2 summarizes key changes in mRSS and tumor response.




Figure 1. Tumor response after radiotherapy (n=11). CR = 5 patients (45.5%), PR = 5 patients (45.5%), SD = 1 patient (9.1%). Abbreviations: CR = complete response; PR = partial response;

Table 2. Pre- and post-transplant SSc and tumor response summary.

Case	Baseline mRSS	mRSS at Follow-Up	Tumor Response	Outcome Description
1	32	14	PR	SSc improved, GGO resolved, breast tumor stable
2	32	6	CR	HLH/SLE remission, lymphoma response
3	32	9	CR	Lung CR, mRSS drop
4	28	13	PR	Skin score improved, tumor stable
5	28	9	CR	Lung CR, SSc resolved
6	32	6	PR	SSc and esophageal tumor both improved
7	32	20	CR	RA and SSc stable, lymphoma CR
8	40	6	PR	SSc resolved, tumor stable
9	28	6	SD	SSc mild improvement, breast cancer stable
10	32	6	CR	Lung CR, SSc improved
11	7 → 28	28	PD	Relapse of SSc and cancer

Abbreviations: mRSS = modified Rodnan skin score; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; GGO = ground-glass opacity; HLH = hemophagocytic lymphohistiocytosis; SLE = systemic lupus erythematosus; RA = rheumatoid arthritis; SSc = systemic sclerosis.

Safety

No transplant-related deaths or organ failures were observed. Gastrointestinal symptoms (nausea, vomiting, diarrhea) occurred in all patients and resolved with symptomatic care. Febrile episodes occurred in 8 patients: 7 due to bacterial infections and 1 due to COVID-19 pneumonia, resolved after convalescent plasma therapy. Thrombocytopenia occurred in all patients; 7 required platelet transfusions. No red cell transfusions or organ toxicity occurred during follow-up.

DISCUSSION

Systemic sclerosis (SSc) remains a challenging autoimmune condition, particularly in its diffuse cutaneous form (dcSSc), which is associated with progressive fibrosis, immune dysregulation, and high mortality. Standard immunosuppressive therapies frequently fail in refractory cases, highlighting the urgent need for novel treatment strategies (7, 15-18). Concurrently, patients with cancer undergoing radiotherapy often experience hematologic toxicity, particularly bone marrow suppression, which increases treatment-related morbidity and mortality (19). The co-occurrence of refractory SSc and malignancy presents a unique therapeutic dilemma that demands a multidisciplinary approach capable of addressing immune overactivation, tumor progression, and myelosuppressive complications of radiotherapy.

Autologous peripheral blood hematopoietic stem cell transplantation (Auto-HSCT) has been established as an effective treatment for autoimmune diseases, including SSc, and a supportive modality in oncology for hematologic recovery during cytotoxic therapies (20-22). In our retrospective study of 11 patients with concurrent refractory SSc and cancer receiving radiotherapy, Auto-HSCT demonstrated dual benefit in improving autoimmune disease control and supporting radiotherapy outcomes. All patients achieved successful hematopoietic recovery with acceptable safety profiles, and eight patients exhibited sustained improvements in SSc clinical and serologic parameters. These results are consistent with prior large trials such as the ASTIS and SCOT studies, which demonstrated significant reductions in mRSS scores and improved event-free survival in dcSSc patients undergoing Auto-HSCT compared to cyclophosphamide therapy alone (23, 24). Importantly, our study contributes novel insights by applying Auto-HSCT in patients undergoing radiotherapy for solid and hematologic malignancies. Patients receiving radiotherapy showed partial or complete tumor responses in most cases, with no grade 3 or higher radiation toxicities. This supports Auto-HSCT's role in mitigating hematologic side effects of radiotherapy, a finding also seen in Auto-HSCT-supported oncology settings (25-27). The absence of transplant-related mortality or organ toxicity in our study is notable given the historically high risks associated with Auto-HSCT in SSc, particularly with myeloablative regimens. This favorable safety profile may be attributed to the use of non-myeloablative conditioning in our cohort, consistent with the ASSIST trial and reinforced by international studies (28, 29). The therapeutic mechanisms of Auto-HSCT likely involve immune reset through depletion of autoreactive lymphocytes and reconstitution of a self-

tolerant immune system, alongside hematopoietic recovery that permits uninterrupted cancer treatment⁽³⁰⁾. This dual mechanism is supported by our observation of improvement not only in mRSS and autoantibody profiles but also in overlap syndromes and stabilization of interstitial lung disease (ILD). The limited response in usual interstitial pneumonia (UIP) versus nonspecific interstitial pneumonia (NSIP) cases is consistent with previous evidence showing better outcomes in inflammatory rather than fibrotic ILD phenotypes⁽³¹⁾. Another relevant observation is the apparent advantage of rituximab-based preconditioning regimens. Patients receiving rituximab in combination with bendamustine and cyclophosphamide showed no disease relapse, supporting evidence for B-cell depletion as a potentiator of Auto-HSCT efficacy in SSc⁽³²⁾. Conversely, patients receiving melphalan-based regimens or cyclophosphamide alone were more likely to relapse, suggesting the importance of regimen intensity and immune modulation. Our study has several limitations that warrant consideration. The small sample size ($n = 11$) and retrospective design limit generalizability and preclude robust statistical inference. Heterogeneity in cancer types, Auto-HSCT protocols, and timing of radiotherapy introduces confounding factors. Although some patients had follow-up periods extending to 36 months, the median follow-up duration of 14.6 months may not capture long-term relapse or late complications. The concurrent administration of radiotherapy and stem cell mobilization also limits the ability to isolate individual effects. Nonetheless, these limitations are offset by the novelty of our approach and the consistent internal results across patients. In conclusion, our findings suggest that Auto-HSCT may serve as a comprehensive treatment strategy for patients with coexisting refractory SSc and cancer undergoing radiotherapy. The observed improvements in disease activity, tumor response, and hematologic recovery support its dual utility. Further prospective, controlled studies with standardized conditioning regimens and longer follow-up are essential to confirm these findings and define best practices for this complex patient population.

CONCLUSION

Autologous peripheral blood hematopoietic stem cell transplantation appears to be a safe and effective therapeutic option for patients with refractory systemic sclerosis undergoing radiotherapy for cancer. It offers dual benefits in immune modulation and hematologic recovery. While promising, these findings warrant validation in larger, controlled studies to optimize protocols and confirm long-term

outcomes.

Acknowledgments: The authors would like to thank the staff of the Department of Hematology, Rheumatology, and Oncology at Pu'er People's Hospital for their support in patient management and data collection.

Funding: This study was supported by the Pu'er Self-Funded Science and Technology Project. The funding body had no role in the design, analysis, interpretation, or writing of the manuscript.

Conflict of interest: All authors declare that they have no conflict of interest relevant to this study.

Ethical considerations: This study was approved by the Ethics Committee of Pu'er People's Hospital (Ethics Approval No.: SKJJ-2024-02) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

Author contributions: Tong Sifan, Liu Zhenghai, Wen Qin: data collection, statistical analysis, interpretation of results, and drafting of the manuscript. Zhang Xi, Zheng Chaoen: conceptualization, study design, critical revision for intellectual content, supervision, and acquisition of funding. Other co-authors: contributed to data acquisition, clinical follow-up, and research support.

AI usage: Authors declare that they did not use AI for preparation of the manuscript except for language editing.

REFERENCES

1. Sobolewski P, Maślińska M, Wiecek M, Łagun Z, Malewska A, Roszkiewicz M, et al. (2019) Systemic sclerosis - multidisciplinary disease: clinical features and treatment. *Reumatologia*, **57**(4): 221-33.
2. Asano Y (2020) The pathogenesis of systemic sclerosis: An understanding based on a common pathologic cascade across multiple organs and additional organ-specific pathologies. *J Clin Med*, **9**(9): 2687.
3. Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T (2023) State-of-the-art evidence in the treatment of systemic sclerosis. *Nat Rev Rheumatol*, **19**(4): 212-26.
4. Mendoza FA, Mansoor M, Jimenez SA (2016) Treatment of rapidly progressive systemic sclerosis: current and futures perspectives. *Expert Opin Orphan Drugs*, **4**(1): 31-47.
5. Wang J, Tian Y, Tang Y, Wang X, Li N, Ren H, et al. (2016) A Phase II prospective nonrandomized trial of magnetic resonance imaging-guided hematopoietic bone marrow-sparing radiotherapy for gastric cancer patients with concurrent chemotherapy. *Oncotargets Ther*, **9**: 2701-7.
6. Konnerth D, Gaasch A, Zinn A, Rogowski P, Rottler M, Walter F, et al. (2024) Hematologic toxicity and bone marrow-sparing strategies in chemoradiation for locally advanced cervical cancer: A systematic review. *Cancers*, **16**(10): 1842.
7. Verginadis II, Citrin DE, Ky B, Feigenberg SJ, Georgakilas AG, Hill-Kayser CE, et al. (2025) Radiotherapy toxicities: mechanisms, management, and future directions. *The Lancet*, **405**(10475): 338-52.
8. Atkins HL, Muraro PA, van Laar JM, Pavletic SZ (2012) Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time? *Biol Blood Marrow Transplant*, **18**(1 Suppl): S177-83.
9. Kawashima-Vasconcelos MY, Santana-Gonçalves M, Zanin-Silva DC, Malmegrim KCR, Oliveira MC (2022) Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis. *Front Immunol*, **13**: 941011.

10. Xu Y, Wang X, Hu Z, Huang R, Yang G, Wang R, *et al.* (2024) Advances in hematopoietic stem cell transplantation for autoimmune diseases. *Heliyon*, **10**(20): e39302.
11. Higashitani K, Takase-Minegishi K, Yoshimi R, Kirino Y, Hamada N, Nagai H, *et al.* (2023) Benefits and risks of haematopoietic stem cell transplantation for systemic sclerosis: A systematic review and meta-analysis. *Modern Rheumatology*, **33**(2): 330-7.
12. Sakkas LI, Simopoulou T, Alexiou I, Liaskos C, Chikanza IC (2025) Stem cell therapy in systemic sclerosis. *Clinical Rheumatology*, **44**(8): 3139-3151.
13. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, *et al.* (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. *Arthritis Rheum*, **65**(11): 2737-47.
14. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirkjak L, *et al.* (2017) Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. *Journal of Scleroderma and Related Disorders*, **2**(1): 11-8.
15. Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, *et al.* (2019) Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. *Bone Marrow Transplant*, **54**(10): 1525-52.
16. Farge D, Ait Abdallah N, Marjanovic Z, Del Papa N (2021) Autologous stem cell transplantation in scleroderma. *Presse Med*, **50**(1): 104065.
17. Fontes HMF, de Freitas JP, Oliveira JHV, de Sousa Moraes ÉA, aes Rego EM, Melo RAM (2024). Causes and risk factors for early death in adult patients with acute promyelocytic leukemia: a real-life experience. *Hematol Transfus Cell Ther.* 2024; **46**(Suppl 6): S122-S128.
18. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, *et al.* (2012) Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European group for blood and marrow transplantation. *Bone Marrow Transplant*, **47**(6): 770-90.
19. Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, Crofford LJ, *et al.* (2018) Systemic Sclerosis as an indication for autologous hematopoietic cell transplantation: Position statement from the American society for blood and marrow transplantation. *Biol Blood Marrow Transplant*, **24**(10): 1961-4.
20. Arruda LC, Clave E, Moins-Teisserenc H, Douay C, Farge D, Toubert A (2016) Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases. *Curr Res Transl Med*, **64**(2): 107-13.
21. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, *et al.* (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. *N Engl J Med*, **378**(1): 35-47.
22. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, *et al.* (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. *JAMA*, **311**(24): 2490-8.
23. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiadu M, Schroeder J, *et al.* (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. *Lancet*, **378**(9790): 498-506.
24. Del Papa N, Pignataro F, Zaccara E, Maglione W, Minniti A (2018) Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis. *Front Immunol*, **9**: 2390.
25. Host L, Nikpour M, Calderone A, Cannell P, Roddy J (2017) Autologous stem cell transplantation in systemic sclerosis: a systematic review. *Clin Exp Rheumatol*, **35** Suppl 106(4):198-207.
26. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, *et al.* (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. *Ann Rheum Dis*, **74**(6): 1188-94.
27. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, *et al.* (2022) Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. *Bone Marrow Transplant*, **57**(8): 1217-39.
28. Gratwohl A, Baldomero H, Passweg J, Frasson F, Niederwieser D, Schmitz N, *et al.* (2003) Hematopoietic stem cell transplantation for hematological malignancies in Europe. *Leukemia*, **17**(5): 941-59.
29. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, *et al.* (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis*, **76**(8): 1327-39.
30. Alnasser SM, Alharbi KS, Almutairy AF, Almutairi SM, Alolayan AM (2023) Autologous stem cell transplant in Hodgkin's and non-Hodgkin's lymphoma, multiple myeloma, and al amyloidosis. *Cells*, **12**(24): 2855.
31. Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, *et al.* (2017) Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. *Blood Adv*, **1**(27): 2742-55.
32. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, *et al.* (2004) Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. *Ann Rheum Dis*, **63**(8): 974-81.